Company profile
Akebia Therapeutics, Inc.
NASDAQ:AKBABiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| VADADUSTAT | approved | — | 31 | approved |
| Ebribafusp Alfa | phase2 | — | 1 | active |
| PRALICIGUAT | phase2 | — | 6 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (37)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02260193 | phase2 | completed | 2014-09-10 | 2015-07-22 | Akebia Therapeutics | 16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis |
| NCT01906489 | phase2 | completed | 2013-07-23 | 2014-09-03 | Akebia Therapeutics | 20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia |
| NCT01381094 | phase2 | completed | 2011-06-15 | 2012-02-16 | Akebia Therapeutics | 42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia |
| NCT06419205 | phase2 | recruiting | 2026-07-30 | 2028-02-01 | Akebia Therapeutics | A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G |
| NCT03799848 | phase1 | completed | 2018-06-12 | 2018-10-18 | Akebia Therapeutics | A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 215192 | NDA | AKEBIA THERAPEUTICS INC | ||||
Loading… | ||||||